<DOC>
	<DOCNO>NCT00003902</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose capecitabine vinorelbine see well work treat old woman metastatic breast cancer without bone involvement .</brief_summary>
	<brief_title>Capecitabine Vinorelbine Treating Older Women Who Have Metastatic Breast Cancer With Without Bone Involvement</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose capecitabine vinorelbine elderly woman ( 65 old ) metastatic breast cancer . - Evaluate efficacy tolerability regimen patient . - Assess time treatment failure regimen first line chemotherapy patient . OUTLINE : This dose-escalation study capecitabine vinorelbine . Patients stratify accord bone involvement ( yes [ close accrual 12/7/04 ] v ) . - Phase I : Patients receive oral capecitabine twice daily day 1-14 vinorelbine IV 6-10 minute day 1 8 . Treatment repeat every 21 day maximum 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos capecitabine vinorelbine maximum tolerate dose ( MTD ) drug determine . The MTD define dose 2 6 patient experience dose limit toxicity . - Phase II : Patients receive capecitabine vinorelbine administer phase I , dose precede MTD . Quality life assess phase II day 1 , 8 , 15 course 1 day 1 course 2-4 . Patients follow every 3 month disease progression start subsequent antitumor treatment . PROJECTED ACCRUAL : A total 98-110 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven adenocarcinoma breast Phase I : Measurable evaluable disease Phase II : Bidimensionally measurable disease No CNS metastases Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 65 Sex : Female Menopausal status : Postmenopausal Performance status : ECOG/SAKK 02 Life expectancy : At least 12 week Hematopoietic : Normal peripheral blood count Hepatic : AST great 2 time upper limit normal ( ULN ) ( great 3 time ULN liver metastasis present ) Renal : Creatinine great 1.5 time ULN Other : No prior concurrent malignancy except adequately treat basal squamous cell skin cancer carcinoma situ cervix No peripheral neuropathy grade 2 high No cognitive impairment severe psychiatric disorder PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : More 6 month since prior adjuvant chemotherapy No prior chemotherapy metastatic locally advanced disease No concurrent chemotherapy Endocrine therapy : Prior hormonal therapy metastatic disease allow No continuous concurrent steroids No concurrent systemic endocrine therapy breast cancer No concurrent endocrine therapy Radiotherapy : No concurrent radiotherapy involve great 30 % bone marrow mucosa Radiotherapy nonindicator lesion allow Surgery : Not specify Other : Bisphosphonates allow indicator lesion nonbone site</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>stage IV breast cancer</keyword>
</DOC>